Thyroid Cancer

Thyroid Cancer

An analysis of thyroid cancer diagnosis and incidence in the United States suggests that there is an epidemic of diagnosis rather than an epidemic of thyroid cancer per se.

There are currently 3 sets of guidelines that outline the management of thyroid nodules. A case in point here.

Would you biopsy a 1 cm mobile nodule in the thyroid area of this 55-year old woman who had mantle field radiation for a childhood cancer?

The FDA has approved sorafenib (Nexavar) for the treatment of metastatic differentiated thyroid cancer.

Data presented at ASCO from the phase III DECISION trial showed treatment with the TKI sorafenib (Nexavar) delayed disease progression by 5 months in patients with metastatic differentiated thyroid cancer that had progressed on radioactive iodine.

This management guide of endocrine malignancies covers the risk factors, diagnosis, screening, and treatment of both thyroid and parathyroid cancers.

The US Food and Drug Administration (FDA) has approved cabozantinib (Cometriq) for the treatment of metastatic medullary thyroid cancer, a rare type of thyroid cancer that makes up about 4% of all cases.


Subscribe to
Please Wait 20 seconds or click here to close